Colorectal Cancer Trial, Recruiting NCT04120935 Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT04120935
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have previously been diagnosed with colorectal cancer, or where there is a strong suspicion of colorectal cancer based on clinical and imaging results
  • People who have stored tissue samples from their colorectal cancer diagnosis available — either as tissue blocks preserved in a special wax (called FFPE blocks) from surgery or biopsy, or at least 10 slides made from that tissue (20 slides is preferred, and tissue blocks are preferred over slides)
  • People who are generally well enough to carry out light activity and care for themselves, as measured by a standard health scoring tool called the ECOG performance scale (a score below 2 is required — confirm with trial site if unsure what this means for a specific situation)

Who may not be able to join:

  • People who currently have, or have been diagnosed with or had a return of, another cancer within the past 5 years — with the exception of certain low-risk skin cancers, early-stage melanoma that has not spread, or early-stage cervical cancer that has not spread
  • People who may not be able to follow the study requirements due to psychological, social, or geographical reasons
  • People who have a known infection with HIV, Hepatitis B, Hepatitis C, or syphilis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Silvia Marsoni, MD, IFOM ETS - The AIRC Institute of Molecular Oncology

Phone: +3902574303799

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Registry
ClinicalTrials.gov
Start date
15 October 2019
Est. completion
1 June 2026

Where this trial is recruiting

🇮🇹 Italy 🇪🇸 Spain

Primary endpoints

Number of patients longitudinally monitored

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov